|
|
Office Locations:
|
600 Montgomery Street, 47th Floor
San Francisco, CA 94111
Phone: 415-430-4200
Fax: 415-371-1840
| | |
|
|
|
|
|
Energy & Clean Tech
Life Sciences & Healthcare
Manufacturing & Industrial
Medical Device
|
|
|
|
Founded in 2008, Savitr Capital is a private investment firm managing assets for Andrew Midler, and focuses its direct capital investments in complex situations often involving the evolution, turnaround, or restructuring of a company. The firm focuses its own resources on a small number of investments at any one time. All capital is internal and permanent which provides for the flexibility to support the long term growth and maximization of value without the constraint of time. Savitr Capital is currently invested in a portfolio of innovation leaders focused in health care and industrial manufacturing. Mr. Midler currently serves on the board of directors of Druggability Technologies, Glytec Systems, CellMDX, Emerald Bio Agriculture, Ancora Heart, BioIQ, and Vascular Therapies. In the majority of these Savitr is a large shareholder and participates at the Board level. Previously, Mr. Midler founded Standard Pacific Capital in 1995. The investment management firm launched with $75M of assets and grew to over $5 billion.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
